Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I Study of Autologous Activated T-cells Targeting the CD19 Antigen and Containing the Inducible Caspase 9 Safety Switch in Subjects With Relapsed/Refractory B-cell Lymphoma

Next Previous
Search
Trial Profile

A Phase I Study of Autologous Activated T-cells Targeting the CD19 Antigen and Containing the Inducible Caspase 9 Safety Switch in Subjects With Relapsed/Refractory B-cell Lymphoma

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 26 Oct 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs ATLCAR CD19 (Primary) ; Bendamustine; Cyclophosphamide; Fludarabine; Rimiducid
  • Indications B-cell lymphoma; Diffuse large B cell lymphoma; Follicular lymphoma; Lymphomatoid granulomatosis; Mantle-cell lymphoma; Marginal zone B-cell lymphoma
  • Focus Adverse reactions

    • Most Recent Events

    • 23 Feb 2023 Planned End Date changed from 12 Oct 2038 to 22 Mar 2043.
    • 23 Feb 2023 Planned primary completion date changed from 12 Oct 2023 to 22 Mar 2027.
    • 22 May 2020 Planned number of patients changed from 12 to 30.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top